psychedelics

An FDA advisory panel voted against recommending the psychedelic MDMA for PTSD, puncturing excitement around the drug’s potential.

The properties of a little-known psychedelic drug may be perfectly tailored to relieve the psychiatric and cognitive symptoms of the disease.

By masking ketamine from placebo for the first time, researchers reveal the importance of accounting for expectancy in trials testing psychoactive drugs.

Psilocybin research was "outlawed" in the 70s, but it's back now. It may offer a powerful new tool for treating addictions to substances such as alcohol, cigarettes, and opioids.

Researchers add analysis to the mix to move beyond anecdotes

BetterLife enters research agreement with UCSD for TD-0148A behavioral pharmacology studies

IntelGenx announces strategic partnership with atai Life Sciences; agreement also includes equity investment by atai

Psychedelics like psilocybin, DMT, and LSD are increasingly welcomed in behavioural and psychiatric research, with implications that extend well beyond neuroscience. This webinar will delve into efforts to transform anecdotal evidence into supported medical interventions through systematic research and controlled clinical trials.